Interaction between MHC Molecules and Brother of Regulator of Imprinting Sites (BORIS) In A Melanoma Cell Line
Article Sidebar
-
BORIS, Cancer Testis Antigen, MHC Molecules, Co-Localization, Immunostaining
Abstract
Identifying the relationship between the human leukocyte antigens (HLA), MHC class I, and MHC class II with tumour antigens expressed in tumour cells may have key points in tumour immunology. If such an association occurs, it could be relevant to the immune regulation of antigen-mediated immunogenicity. If the intracellular tumour antigen is an immunogenic, it can potentially be presented by MHC molecules to T-cells. A direct consequence of this process is T-cell recognition and thus the development of T-cells capable of targeting the tumour. Key experiments were carried out designed to physically identify the new cancer testis (CT) antigen; BORIS (brother of regulator of imprinting site), and its potential partners. The double immunostaining technique by immunofluorescence method was applied to study co-localization between MHC molecules (class I and II) and BORIS. Such co-localization studies provide an insight into the intracellular distribution and association of BORIS. This piece of work aims to detect the expression of the tumour antigen of interest (BORIS) in the candidate tumour cell line (MD-MB-435) and to study the co-localization between BORIS (a potential tumour antigen) with HLA-A,B,C and HLA-DR molecules. The results showed that the co-localization ratio between HLA-DR molecules and BORIS (34.06 %) was slightly higher than the ratio between BORIS and HLA-A,B,C molecules (31.663 %); P < 0.05 ***. The co-localization between BORIS and MHC class I or class II molecules could highlight possible interactions between these proteins. Future work on this part of the research should be continued with different tumour cell lines.
Full text article
References
[1]-van der Bruggen,P., Traversari, C . , Chomez, P ., Lurquin, C ., De Plaen, E. , Van den Eynde, B ., Knuth, A and Boon, T. (1991). A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science, 254, 1643–1647.
[2]-Scanlan, M.J., Gure, A.O., Jungbluth, A.A., Old, L.Jand Chen, Y.T.(2002). Cancer/testis antigens: an expanding family of targets for cancer immunotherapy.Immunol Rev,188, 22-32.
[3]-Scanlan,M.J., Simpson, A.J.G and Old, L.J. (2004). The cancer/testis genes: Review, standardization, and commentary.Cancer Immunity, 4, 1.
[4]-Boel, P., Wildmann, C., Sensi, M.L., Brasseur, R., Renauld, J.-C., Coulie, P., Boon, T and van der Bruggen, P.(1995). BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity. 2, 167-175.
[5]-De Backer,O., Arden, K.C., Boretti, M., et al., (1999). Characterization of the GAGEGenes That Are Expressed in Various Human Cancers and in Normal Testis. Cancer Res, 59, 3157-3165.
[6]-Sugita,Y., Wada, H., Fujita, S., et al., (2004). NY-ESO-1 Expression and Immunogenicity in Malignant and Benign Breast Tumors. Cancer Res, 64, 2199-2204.
[7]-Jungbluth,A.A., Busam, K.J., Kolb, D, Iversen, K., Coplan, K., Chen, Y-T., Spagnoli, G.C and Old, L.J. (2000). Expression of mage-antigens in normal tissues and cancer. Int. J. Cancer,85,460–465.
[8]-Jones,T.A., Ogunkolade, B.W., Szary, J., Aarum, J., Mumin, M.A., Patel, S., Pieri, C.A and Sheer, D. (2011).Widespread Expression of BORIS/CTCFL in Normal and Cancer Cells. PLoS ONE, 6, e22399.
[9]-Gnjatic,S., Nishikawa, H., Jungbluth, A.A., Güre, A.O., Ritter, G., Knuth, A., Chen, Y-T and Old, L.I. (2006). NY-ESO-1: Review of an immunogenic tumor antigen. Advances in Cancer Research, 95, 1-30.
[10]-Klenova,E.M., Morse, H.C., Ohlsson, R and Lobanenkov, V.V. (2002). The novel BORIS+ CTCF gene family is uniquely involvedin the epigenetics of normal biology and cancer. Seminars in cancer biology, 12, 399–414.
[11]-Risinger,J.I., Chandramouli, G.V.R ., Maxwell, G.L ., et al., (2007). Global Expression Analysis of Cancer/Testis Genes in Uterine Cancers Reveals a High Incidence of BORIS Expression. Clin Cancer Res, 13, 1713-1719.
[12]-D'Arcy, V., Pore, N., Docquier, F., et al., (2008).BORIS, a paralogue of the transcription factor, CTCF, is aberrantly expressed in breast tumours.British Journal of Cancer, 98,571–579.
[13]-D'Arcy, V.,Abdullaev, Z.K.,Pore, N.,Docquier, F.,Torrano, V.,Chernukhin, I.,Smart, M.,Farrar, D.,Metodiev, M.,Fernandez N.,Richard, C.,Delgado, M.D.,Lobanenkov, V.,Klenova, E. (2006). The potential of BORIS detected in the leukocytes of breast cancer patients as an early marker of tumorigenesis. Clin Cancer Res 12, 5978-86.
[14]-Zhang, Y., Fang, M ., Song, Y.,Ren, J ., Fang, Jand Wang, X. ( 2017). Brother of Regulator of Imprinted Sites (BORIS) suppresses apoptosis in colorectal cancer. Sci Rep. 7, 40786.
[15]-Benlalam,H., Linard, B., Guilloux, Y., Moreau-Aubry, A.,Derré, L., Diez,E., Dreno, B.,Jotereau, Fand Labarrière, N. (2003). Identification of Five New HLA-B*3501-Restricted Epitopes Derived from Common Melanoma-Associated Antigens, Spontaneously Recognized by Tumor-Infiltrating Lymphocytes. The Journal of Immunology, 171,6283-6289.
[16]-Chen,Q., Jackson, H., Parente, P., et al., (2004). Immunodominant CD4 responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant. PNAS, 101, 9363-9368.
[17]-Jackson, H., Dimopoulos, N., Mifsud, N.A., et al., ( 2006). Striking immunodominance hierarchy of naturally occurring CD8+ and CD4+ T cell responses to tumor antigen NY-ESO-1.J Immunol, 176, 5908-17.
[18]-Jäger,E., Chen,Y-T., Drijfhout,J.W., et al., (1998). Simultaneous Humoral and Cellular Immune Response against Cancer–Testis Antigen NY-ESO-1: Definition of Human Histocompatibility Leukocyte Antigen (HLA)-A2–binding Peptide Epitopes.J Exp Med., 187,265–270.
[19]-Jäger,E., Jäger,D, Karbach,J., et al., (2000). Identification of NY-ESO-1 Epitopes Presented by Human Histocompatibility Antigen (HLA)-DRB4*0101–0103 and Recognized by CD4+ T Lymphocytes of Patients with NY-ESO-1–expressing Melanoma.J Exp Med.,191,625–630.
[20]-Jäger, E., Karbach, J., Gnjatic, S., et al., (2002). Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51. Cancer Immun., 2, 12.
[21]-Gnjatic,S., Nagata, Y., Jäger, E., et al., (2000). Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele. PNAS , 97,10917–10922.
[22]-Mandic,M., Castelli, F., Janjic, B., et al., (2005). One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma. J. Immunol., 174, 1751-1759.
[23]-Wang, R-F., Johnston, S.L., Zeng, G., Topalian, S.L., Schwartzentruber, D.J and Rosenberg, S.A. (1998). A Breast and Melanoma-Shared Tumor Antigen: T Cell Responses to Antigenic Peptides Translated from Different Open Reading Frames. J Immunol ,161 , 3596–3606.
[24]-Zarour, H.M., Maillere, B., Brusic, V., et al., (2002). NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1-and Th2-type tumor-reactive CD4+ T cells. Cancer Res.62, 213-8.
[25]-Zeng, G., Touloukian, C.E., Wang, X., Restifo, N.P., Rosenberg, S.A and Wang, R-F. (2000). Identification of CD4+ TCell Epitopes from NY-ESO-1 Presented by HLA-DR Molecules. J Immunol, 165, 1153–1159.
[26]-Zeng, G., Wang, X., Robbins, P.F., Rosenberg, S.A and Wang, R-F. (2001). CD4+ T cell recognition of MHC class II-restricted epitopesfrom NY-ESO-1 presented by a prevalent HLA DP4 allele: Association with NY-ESO-antibody production. PNAS, 98,3964–3969.
[27]-Loukinov, D., Ghochikyan, A., Mkrtichyan, M ., Ichim, T.E., Lobanenkov, V.V., Cribbs, D.H and Agadjanyan, M.G. (2006). Antitumor Efficacy of DNA Vaccination to the Epigenetically Acting Tumor Promoting Transcription Factor BORIS and CD80 Molecular Adjuvant. Journal of Cellular Biochemistry , 98, 1037–1043.
[28]-Ghochikyan, A., Mkrtichyan, M ., Loukinov, D ., Mamikonyan, G., Pack, S.D .,Movsesyan, N., Ichim, T.E., Cribbs, D.H., Lobanenkov, V.V and Agadjanyan, M.G. (2007). Elicitation of T Cell Responses to Histologically Unrelated Tumors by Immunization with the Novel Cancer-Testis Antigen, Brother of the Regulator of Imprinted Sites. The Journal of Immunology, 178, 566 –573.
[29]-Mkrtichyan, M., Ghochikyan, A., Loukinov, D., Davtyan, H., Ichim, T.E., Cribbs, D.H., Lobanenkov, V.V and Agadjanyan, M.G. (2008). DNA, but not protein vaccine based on mutated BORIS antigen significantly inhibits tumour growth and prolongs the survival of mice. Gene Therapy ,15, 61–64.
[30]-Mkrtichyan,M., Ghochikyan, A., Davtyan, H., et al., (2011). Cancer-testis antigen, BORIS based vaccine delivered by dendritic cells is extremely effective against a very aggressive and highly metastatic mouse mammary carcinoma. Cell Immunol, 270, 188–97.
[31]-Hong,J.A., Kang, Y., Abdullaev, Z., et al.,(2005). Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells. Cancer research , 65, 7763-74.
[32]-Vatolin,S., Abdullaev, Z., Pack, S.D., et al., (2005). Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes. Cancer research, 65, 7751. AACR.
[33]-Kang, Y., Hong, J.A, Chen, G.A., et al., (2005). Modulation ofNY-ESO-1 expression in lung cancer cells by brother of the regulator of imprinted sites [abstract], Proc Amer Assoc Cancer Res (AACR), Abstract no. 36, 643
Authors
This work is licensed under a Creative Commons Attribution 4.0 International License.
In a brief statement, the rights relate to the publication and distribution of research published in the journal of the University of Sebha where authors who have published their articles in the journal of the university of Sebha should how they can use or distribute their articles. They reserve all their rights to the published works, such as (but not limited to) the following rights:
- Copyright and other property rights related to the article, such as patent rights.
- Research published in the journal of the University of Sebha and used in its future works, including lectures and books, the right to reproduce articles for their own purposes, and the right to self-archive their articles.
- The right to enter a separate article, or for a non-exclusive distribution of their article with an acknowledgment of its initial publication in the journal of Sebha University.
Privacy Statement The names and e-mail addresses entered on the Sabha University Journal site will be used for the aforementioned purposes only and for which they were used.